{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:19:59Z","timestamp":1789946399770,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T00:00:00Z","timestamp":1124755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1038\/sj.bjc.6602750","type":"journal-article","created":{"date-parts":[[2005,8,31]],"date-time":"2005-08-31T13:16:29Z","timestamp":1125494189000},"page":"504-509","source":"Crossref","is-referenced-by-count":80,"title":["Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures"],"prefix":"10.1038","volume":"93","author":[{"given":"G","family":"Apolone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Joppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Bertele'","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Garattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,23]]},"reference":[{"key":"BF6602750_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7525-1-3","volume":"1","author":"G Apolone","year":"2003","unstructured":"Apolone G (2003) Outcome and clinical research in oncology. The need for an integration. Health Qual Life Outcomes 1: 3","journal-title":"Health Qual Life Outcomes"},{"key":"BF6602750_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0753-3322(01)00144-5","volume":"55","author":"RC Bast","year":"2001","unstructured":"Bast RC, Mills GB, Young RC (2001) Translational research: traffic on the bridge. Biomed Pharmacother 55: 565\u2013571","journal-title":"Biomed Pharmacother"},{"key":"BF6602750_CR3","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/S0959-8049(98)00334-7","volume":"34","author":"F Berrino","year":"1999","unstructured":"Berrino F, Gatta G, Chessa E, Valente F, Capocaccia R, the Eurocare Working Group (1999) Introduction: the Eurocare II study. Eur J Cancer 34: 2139\u20132153","journal-title":"Eur J Cancer"},{"key":"BF6602750_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1200\/JCO.2002.06.140","volume":"20","author":"RA Betensky","year":"2002","unstructured":"Betensky RA, Louis DN, Cairncross JG (2002) Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20: 2495\u20132499","journal-title":"J Clin Oncol"},{"key":"BF6602750_CR5","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1200\/JCO.2002.99.183","volume":"20","author":"M Castro","year":"2002","unstructured":"Castro M (2002) The simpleton's error in drug development. J Clin Oncol 20: 4606\u20134607","journal-title":"J Clin Oncol"},{"issue":"S4","key":"BF6602750_CR6","first-page":"iii145","volume":"15","author":"M Chapelin","year":"2004","unstructured":"Chapelin M, Pignatti F, Papadouli I, Doan-Tran D, Papaluca Amati M, Moulon I, Le Courtois P (2004) Design and endpoints of pivotal cancer clinical trials for registration in the European Union: The European Medicines Agency (EMEA) 10-years experience. Ann Oncol 15(S4): iii145","journal-title":"Ann Oncol"},{"key":"BF6602750_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/009286150203600127","volume":"36","author":"O Chassany","year":"2002","unstructured":"Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment Group (2002) Patient reported outcomes: the example of health related quality of life \u2013 a European guidance for the improved integration of HRQOL assessment in the drug regulatory process. Drug Inf J 36: 209\u2013238","journal-title":"Drug Inf J"},{"key":"BF6602750_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/bcr8","volume":"1","author":"MP Coleman","year":"1999","unstructured":"Coleman MP (1999) Opinion: why the variation in breast cancer survival in Europe? Breast Cancer Res 1: 22\u201326","journal-title":"Breast Cancer Res"},{"key":"BF6602750_CR9","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jama.291.9.1120","volume":"291","author":"WF Crowley","year":"2004","unstructured":"Crowley WF, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H, Reece EA, Catanese V, Johnson SB, Dobs A, Genel M, Korn A, Reame N, Bonow R, Grebb J, Rimoin D (2004) Clinical research in the United States at a crossroads. Proposal for a novel public\u2013private partnership to establish a national clinical research enterprise. JAMA 291: 1120\u20131126","journal-title":"JAMA"},{"key":"BF6602750_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/jnci\/djh279","volume":"96","author":"R Dagher","year":"2004","unstructured":"Dagher R, Johnson J, Williams G, Keegan P, Pazdur R (2004) Accelerated approval of oncology products. A decade of experience. J Natl Cancer Inst 96: 1500\u20131509","journal-title":"J Natl Cancer Inst"},{"key":"BF6602750_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/bmj.325.7358.269","volume":"325","author":"S Garattini","year":"2002","unstructured":"Garattini S, Bertele' V (2002) Efficacy, safety and cost of new anticancer drugs. Br Med J 325: 269\u2013271","journal-title":"Br Med J"},{"key":"BF6602750_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(04)17523-5","volume":"364","author":"R Horton","year":"2004","unstructured":"Horton R (2004) Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 364: 1995\u20131996","journal-title":"Lancet"},{"key":"BF6602750_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","volume":"21","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Williams G, Pazdur R (2003) Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21: 1404\u20131411","journal-title":"J Clin Oncol"},{"key":"BF6602750_CR14","first-page":"77","volume":"22","author":"C Leaf","year":"2003","unstructured":"Leaf C (2003) Why we are loosing the war against cancer and how to win it. Fortune March 22: 77\u201394","journal-title":"Fortune March"},{"key":"BF6602750_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jnci\/92.3.195","volume":"92","author":"SJ Lee","year":"2000","unstructured":"Lee SJ, Craig CE, Weeks JC (2000) Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst 92: 195\u2013204","journal-title":"J Natl Cancer Inst"},{"key":"BF6602750_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1056\/NEJMsa035507","volume":"389","author":"C Lenfant","year":"2003","unstructured":"Lenfant C (2003) Shattuck lecture \u2013 clinical research to clinical practice \u2013 lost in translation. N Eng J Med 389: 868\u2013874","journal-title":"N Eng J Med"},{"key":"BF6602750_CR17","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0959-8049(00)00283-5","volume":"36","author":"F Levi","year":"2000","unstructured":"Levi F, Lucchini F, Negri E, La Vecchia C (2000) The decline in cancer mortality in the European Union, 1988\u20131996. Eur J Cancer 36: 1965\u20131968","journal-title":"Eur J Cancer"},{"key":"BF6602750_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal grow factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129\u20132139","journal-title":"N Engl J Med"},{"key":"BF6602750_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1023\/A:1011655500247","volume":"12","author":"JG McVie","year":"2002","unstructured":"McVie JG (2002) Are European cancer patients getting a fair deal? Ann Oncol 12: 1033\u20131035","journal-title":"Ann Oncol"},{"key":"BF6602750_CR20","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.287.18.2424","volume":"287","author":"DG Nathan","year":"2002","unstructured":"Nathan DG (2002) Careers in translational clinical research \u2013 historical perspectives, future challenges. JAMA 287: 2424\u20132427","journal-title":"JAMA"},{"key":"BF6602750_CR21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer. Correlation with clinical response to gefitinib therapy. Science 304: 1497\u20131500","journal-title":"Science"},{"key":"BF6602750_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1040-8428(02)00009-4","volume":"42","author":"F Pignatti","year":"2002","unstructured":"Pignatti F, Aronsson B, Vamvakas S, Wade G, Papadouli I, Papaluca M, Moulon I, Le Courtois P (2002) Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology. Crit Rev Oncol Hemat 42: 123\u2013135","journal-title":"Crit Rev Oncol Hemat"},{"key":"BF6602750_CR23","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","volume":"292","author":"BM Psaty","year":"2004","unstructured":"Psaty BM, Furberg CD, Ray WA, Weiss NS (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions. Use of cerivastatin and risk of rhabdomyolisis. JAMA 292: 2622\u20132631","journal-title":"JAMA"},{"key":"BF6602750_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00004479-200404000-00005","volume":"27","author":"K Redmond","year":"2004","unstructured":"Redmond K (2004) The US and European regulatory systems: a comparison. J Ambulatory Care Manage 27: 105\u2013114","journal-title":"J Ambulatory Care Manage"},{"key":"BF6602750_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMsb040064","volume":"351","author":"TG Roberts","year":"2004","unstructured":"Roberts TG, Chabner BA (2004) Beyond the fast track for drug approvals. N Eng J Med 351: 501\u2013505","journal-title":"N Eng J Med"},{"key":"BF6602750_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil GC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719\u2013726","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602750.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602750","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602750.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:17:49Z","timestamp":1684412269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,23]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF6602750"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602750","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,23]]}}}